Endo International (ENDP) shares surged Tuesday after the specialty-healthcare firm booked better-than-expected second-quarter earnings. Profits came in at $0.86 a share, topping estimates by 16 percent. Sales of $921 million were roughly seven percent above forecasts. The company also announced the appointment of Joseph Ciaffoni -- a former senior vice president at Biogen (BIIB) -- as president of its U.S. branded businesses. Shares of Endo are up 45 percent over the past three months.
More from Video
How quickly do we find support, is what we'll want to know now, as the correction is occurring while economic optimism builds.
Despite the president's promise of no stimulus until after Nov. 3, there are no signs yet that this is the sort of correlated selling that leads to a deep correction.
Salesforce, Amgen and Honeywell will give a lift to the DJIA going forward.
CAG has hung onto the bulk of its recent gains, and could rise to the $50 area, according to the charts and indicators.